Navigating Obesity Market Entry and Pipeline Transformation

Amgen Inc. is a global biotechnology company headquartered in Thousand Oaks, California, focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Founded in 1980, the company has grown into one of the world's largest independent biotech firms, employing approximately 27,000 people worldwide and operating in over 100 countries.

The company generates revenue through a diversified portfolio of biologic medicines across several therapeutic areas. Its key products include Enbrel (etanercept) for autoimmune diseases, Prolia (denosumab) for osteoporosis, Repatha (evolocumab) for hypercholesterolemia, Otezla (apremilast) for psoriasis, and a range of oncology and supportive care products. Amgen also maintains a substantial biosimilar portfolio, offering more affordable versions of established biologics.

Amgen's customer base includes healthcare providers, hospitals, clinics, and pharmacies, with revenue derived primarily from prescription drug sales. The company's commercial model combines a direct sales force for specialty products with partnerships and distributors for broader market reach. In 2025, the company generated approximately $34B in revenue, with the United States accounting for roughly 75% of total sales.

The company's scale is substantial, with manufacturing facilities in the US, Europe, and Asia, and a supply chain designed to support global distribution of temperature-sensitive biologics. Amgen's research and development organization focuses on six core therapeutic areas: oncology, inflammation, bone health, cardiovascular disease, neuroscience, and nephrology. The company's innovation strategy combines internal discovery with strategic partnerships and acquisitions to build a robust pipeline of first-in-class and best-in-class medicines.

• Near-Term Drivers: The immediate growth trajectory is anchored by the continued expansion of recently launched products. Tezspire (tezepelumab) in severe asthma and Lumakras (sotorasib) in KRAS-mutated lung cancer are both gaining market traction. Additionally, the biosimilar portfolio, including Amgevita (adalimumab biosimilar) and Mvasi (bevacizumab biosimilar), continues to capture share from reference products. The company's recent acquisition of Horizon Therapeutics added rare disease assets, including Tepezza for thyroid eye disease, which is growing rapidly.

• Medium-Term Catalysts: Beyond MariTide, several pipeline assets could drive growth in the 2027-2029 timeframe. Tarlatamab (AMG 757) in small-cell lung cancer has demonstrated compelling efficacy data and could address a significant unmet need. The company is also developing AMG 133 (obesity), AMG 510 (oncology), and multiple earlier-stage assets in cardiovascular and neuroscience. Successful execution across these programs could re-accelerate revenue growth to high-single-digit levels.

• Obesity Franchise Potential: Despite the recent data disappointment, Amgen's obesity franchise still represents a meaningful growth opportunity. MariTide's once-monthly dosing could differentiate it in a market dominated by weekly injectables. The company is also exploring oral formulations and combination approaches that could expand the addressable patient population. If approved, this franchise could contribute $5-10B in peak annual sales, though the timeline has likely extended given the recent setback.

• International Expansion: Amgen continues to expand its international footprint, particularly in emerging markets where biologic adoption is increasing. The company's recent launches in China and other Asia-Pacific markets for key products like Prolia and Repatha are gaining traction. International revenue growth, combined with US market penetration, supports a medium-term revenue CAGR of approximately 4-6%.

The financial trajectory reflects Amgen's transition from a period of patent expirations to a growth phase driven by new product launches. Revenue growth accelerated in 2024 following the Horizon acquisition, which added approximately $4B in annualized sales. However, gross margins have contracted modestly due to product mix shifts toward biosimilars and the inclusion of Horizon's rare disease portfolio, which carries different cost structures.

Operating margins have declined from peak levels due to increased R&D investment (approximately 20% of revenue) and higher selling, general, and administrative expenses associated with launching new products. The company's EPS growth has nonetheless remained positive, supported by aggressive share buybacks and favorable tax positioning. Free cash flow generation remains robust, funding both organic investment and strategic M&A while supporting a growing dividend. Looking forward, margin stabilization and potential operating leverage from new product launches could support EPS growth in the high-single-digit range.

The global biotechnology industry is characterized by rapid innovation, high barriers to entry, and substantial R&D investment requirements. The addressable market for Amgen's core therapeutic areas—oncology, inflammation, and cardiovascular disease—exceeds $200B annually. Within this landscape, Amgen competes with both large-cap pharmaceutical companies and specialized biotech firms.

The obesity treatment market, which has become a key battleground, is projected to reach $100-150B by 2030, attracting significant investment from multiple players. This market's rapid expansion is driven by high patient demand, improved drug efficacy, and expanding insurance coverage. Amgen's positioning in this space, while challenged by recent data, remains credible given its manufacturing capabilities and commercial infrastructure.

Key Competitors:

• Eli Lilly (LLY): The current leader in obesity with Zepbound (tirzepatide), which has demonstrated superior weight loss in clinical trials. Lilly's aggressive investment in manufacturing capacity and its oral GLP-1 candidate position it to maintain leadership.
• Novo Nordisk (NVO): Pioneer in the GLP-1 space with Wegovy and Ozempic, though facing competitive pressure from Lilly's offerings. Novo's pipeline includes next-generation candidates that could extend its franchise.
• Roche (RHHBY): Emerging competitor with a differentiated oral GLP-1 candidate (CT-996) and a recent acquisition of Carmot Therapeutics, signaling serious intent in the obesity space.
• Pfizer (PFE): Has faced setbacks in oral GLP-1 development but remains a potential entrant with its danuglipron program under reformulation.

Amgen's competitive positioning is differentiated by its focus on convenient dosing (monthly versus weekly) and potential differentiation in weight maintenance. However, the company faces significant challenges in matching the efficacy demonstrated by Lilly's and Novo's leading products. In its core oncology and inflammation franchises, Amgen competes with Bristol-Myers Squibb, Merck, and AbbVie, where its position is more established and defensible.

Amgen's current valuation reflects a market that has partially de-rated the stock following the MariTide setback. At $404.42 per share, the stock trades at approximately 25.1x trailing EPS of $16.09. This multiple sits below the company's five-year average forward P/E of approximately 13-15x, suggesting that the market has historically assigned a lower multiple to Amgen's more mature, slower-growth profile.

Discounted Cash Flow Analysis: Applying a DCF model with conservative assumptions—a 7% revenue CAGR through 2032, a terminal growth rate of 2.5%, and a weighted average cost of capital of 7.5%—yields an intrinsic value range of $380-$420 per share. The base case incorporates 40% probability-weighted success for MariTide with peak sales of $4B, while the bear case assumes complete failure in obesity. The recent share price suggests the market is pricing in a scenario closer to the bear case, potentially creating upside if pipeline execution improves.

Comparable Company Valuation:

Relative to large-cap biopharma peers, Amgen trades at a discount to growth-oriented companies like Lilly and Novo but at a premium to more mature, patent-expiry-exposed names like BMS and Gilead. This positioning is appropriate given Amgen's hybrid profile—established cash flows with pipeline optionality. The stock's beta of 0.43 indicates lower systematic risk than the broader market, supporting a slightly lower cost of equity and higher intrinsic value.

• Obesity Franchise Failure: The most significant company-specific risk centers on MariTide's clinical and regulatory trajectory. Recent data showing weight-loss plateau at 52 weeks could undermine the product's competitive positioning, potentially reducing peak sales estimates by 50% or more. If the FDA requires additional trials or the product demonstrates safety concerns, the obesity opportunity could be substantially diminished or eliminated.

• Patent Expirations and Biosimilar Competition: Several core products face patent cliffs in the coming years, including Prolia (2030) and Repatha (2035 in the US, but earlier in Europe). Biosimilar competition to Enbrel in Europe has already eroded sales, and similar pressure could emerge in the US market. The company's ability to offset these declines with new product launches is critical to maintaining revenue stability.

• Regulatory and Pricing Pressure: The pharmaceutical industry continues to face scrutiny over drug pricing, with the Inflation Reduction Act enabling Medicare price negotiations. Amgen's products selected for negotiation, including Enbrel and Prolia, could face price reductions that impact revenue growth. Additionally, broader healthcare reform could introduce pricing controls that compress margins across the industry.

• Clinical Development Setbacks: Beyond obesity, Amgen's pipeline carries inherent clinical risk. Late-stage failures in oncology or neuroscience programs could impair growth expectations and trigger further multiple compression. The company's history includes several high-profile Phase 3 failures, underscoring the binary nature of biotech R&D.

• Integration and Execution Risk: The Horizon acquisition, while strategically sound, introduces integration risk. Achieving targeted synergies, retaining key talent, and effectively commercializing Horizon's rare disease assets are essential to realizing the deal's value. Any integration missteps could distract management and consume resources that might otherwise be directed toward pipeline advancement.